UTHR vs. ALNY, BIIB, INCY, BMRN, EXEL, NBIX, EXAS, HALO, MDGL, and RGEN
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.
United Therapeutics vs.
United Therapeutics (NASDAQ:UTHR) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.
Alnylam Pharmaceuticals received 566 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 62.58% of users gave United Therapeutics an outperform vote.
United Therapeutics has a net margin of 40.31% compared to Alnylam Pharmaceuticals' net margin of -12.37%. United Therapeutics' return on equity of 19.22% beat Alnylam Pharmaceuticals' return on equity.
United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
United Therapeutics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
United Therapeutics currently has a consensus target price of $388.25, suggesting a potential upside of 35.62%. Alnylam Pharmaceuticals has a consensus target price of $315.58, suggesting a potential upside of 33.08%. Given United Therapeutics' higher probable upside, equities research analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 11.9% of United Therapeutics shares are owned by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, United Therapeutics had 2 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 27 mentions for United Therapeutics and 25 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 1.48 beat Alnylam Pharmaceuticals' score of 0.84 indicating that United Therapeutics is being referred to more favorably in the media.
Summary
United Therapeutics beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UTHR) was last updated on 4/15/2025 by MarketBeat.com Staff
Buy UTHR Stock Free UTHR Stock Alerts